Human BCMA/TNFRSF17 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human BCMA/TNFRSF17 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: TNFRSF17

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human BCMA/TNFRSF17 DuoSet ELISA, 15 Plate

• B cell maturation antigen
• B-cell maturation protein
• BCMA
• BCMAtumor necrosis factor receptor superfamily member 17
• BCMB-cell maturation factor
• CD269 antigen
• CD269
• TNFRSF13A
• TNFRSF17
• tumor necrosis factor receptor superfamily, member 17

Background

B cell maturation protein (BCMA) is a member of the TNF receptor superfamily (TNFRSF17). BCMA is expressed in immune organs and mature Bcell lines. Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment. BCMA binding to APRIL or BAFF stimulates IgM production in peripheral blood B cells and increases the survival of cultured B cells. Mature human and mouse BCMA share 86% amino acid sequence identity.

Publications for BCMA/TNFRSF17 (DY193)(10)

Publications using DY193

• Burchett, R;Morris, CG;Ishak, M;Serniuck, NJ;Cummings, DT;Baker, CL;Marius, R;Kazdhan, N;Silvestri, CM;Bell, J;Lichty, BD;Walsh, SR;Wan, Y;Hammill, JA;Bramson, JL; A universal boosting strategy for adoptive T cell therapy using a paired vaccine/chimeric antigen receptor Cancer immunology research 2025-12-08 [PMID: 41359369] (Human)
• Lee, H;Ahn, S;Maity, R;Leblay, N;Ziccheddu, B;Truger, M;Chojnacka, M;Cirrincione, A;Durante, M;Tilmont, R;Barakat, E;Poorebrahim, M;Sinha, S;McIntyre, J;M Y Chan, A;Wilson, H;Kyman, S;Krishnan, A;Landgren, O;Walter, W;Meggendorfer, M;Haferlach, C;Haferlach, T;Einsele, H;Kortüm, MK;Knop, S;Alberge, JB;Rosenwald, A;Keats, JJ;Rasche, L;Maura, F;Neri, P;Bahlis, NJ; Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Nature medicine 2023-08-31 [PMID: 37653344] (Human)
• L Bolkun, M Tynecka, T Wasiluk, J Piszcz, A Starosz, K Grubczak, M Moniuszko, A Eljaszewic A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia Journal of Clinical Medicine, 2022-08-09;11(16):. 2022-08-09 [PMID: 36012902] (Human)
• A Visram, C Soof, SV Rajkumar, SK Kumar, S Bujarski, TM Spektor, RA Kyle, JR Berenson, A Dispenzier Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients Blood Cancer Journal, 2021-06-24;11(6):120. 2021-06-24 [PMID: 34168119] (Human)
• S Piantoni, F Regola, S Masneri, M Merletti, T Lowin, P Airò, A Tincani, F Franceschi, L Andreoli, G Pongratz Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy Frontiers in Pharmacology, 2021-05-21;12(0):666971. 2021-05-21 [PMID: 34093196] (Human)
• T Robinson, A Abdelhak, T Bose, E Meinl, M Otto, UK Zettl, R Dersch, H Tumani, S Rauer, A Huss Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis Cells, 2020-11-25;9(12):. 2020-11-25 [PMID: 33255854] (Human)
• L Perez-Amil, G Suñe, A Antoñana-V, M Castella, A Najjar, J Bonet, N Fernández-, S Inogés, A López, C Bueno, M Juan, A Urbano-Isp, B Martín-Ant Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma Haematologica, 2021-01-01;0(0):. 2021-01-01 [PMID: 31919085] (Mouse)
• Cohen A, Garfall A, Stadtmauer E, Melenhorst J, Lacey S, Lancaster E, Vogl D, Weiss B, Dengel K, Nelson A, Plesa G, Chen F, Davis M, Hwang W, Young R, Brogdon J, Isaacs R, Pruteanu-Malinici I, Siegel D, Levine B, June C, Milone M B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest, 2019-03-21;130(0):. 2019-03-21 [PMID: 30896447] (Human)
• E Schuh, A Musumeci, FS Thaler, S Laurent, JW Ellwart, R Hohlfeld, A Krug, E Meinl Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement J. Immunol, 2017-03-10;0(0):. 2017-03-10 [PMID: 28283566] (Human)
• Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol., 2009-09-10;30(1):99-105. 2009-09-10 [PMID: 19763798] (Human)

Bioinformatics

• Gene Symbol: TNFRSF17